Literature DB >> 27788856

Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials.

Stuart J Pocock1, George Bakris2, Deepak L Bhatt3, Sandeep Brar4, Martin Fahy4, Bernard J Gersh5.   

Abstract

Regression to the mean (RTM) describes the tendency for an extreme measurement on 1 occasion to become less extreme when measured again. RTM may affect clinical trial data interpretation when the outcome measure has high variability. We investigated RTM in the SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) trial of renal denervation versus a sham procedure. Analysis of covariance was performed on the 6-month change in systolic blood pressure, estimating a mean treatment difference of -4.11 mm Hg (95% confidence interval: -8.44 to 0.22 mm Hg; p = 0.064), which was similar to the unadjusted difference but with a smaller confidence interval. RTM occurred in both arms, but it had a negligible effect on the observed treatment difference. A second example concerns changes in hemoglobin A1c in a nonrandomized study. These findings emphasize the importance of incorporating RTM and analysis of covariance into the design and reporting of clinical studies of how treatments affect time changes in quantitative outcomes. (Renal Denervation in Patients With Uncontrolled Hypertension [SYMPLICITY HTN-3]; NCT01418261).
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  blood pressure; hemoglobin A1c; randomized controlled trials as topic; renal denervation; statistical regression

Mesh:

Substances:

Year:  2016        PMID: 27788856     DOI: 10.1016/j.jacc.2016.07.775

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

Review 1.  Renal denervation: dark past, bright future?

Authors:  Marshall Heradien; Felix Mahfoud; Doug Hettrick; Paul Brink
Journal:  Cardiovasc J Afr       Date:  2019 Sep/Oct       Impact factor: 1.167

2.  Extended-Release Carvedilol in the Treatment of Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial.

Authors:  Kang-Ling Wang; Chih-Yuan Fang; Wen-Ter Lai; Tzung-Dau Wang; Kwo-Chang Ueng; Kuo-Yang Wang; Ji-Hung Wang; Kou-Gi Shyu; Chern-En Chiang
Journal:  Acta Cardiol Sin       Date:  2021-03       Impact factor: 2.672

3.  Impact of a Patient-Centered Behavioral Economics Intervention on Hypertension Control in a Highly Disadvantaged Population: a Randomized Trial.

Authors:  Martin F Shapiro; Suzanne B Shu; Noah J Goldstein; Ronald G Victor; Craig R Fox; Chi-Hong Tseng; Sitaram Vangala; Braden K Mogler; Stewart B Reed; Estivali Villa; José J Escarce
Journal:  J Gen Intern Med       Date:  2019-09-12       Impact factor: 6.473

4.  Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis.

Authors:  Lucas Lauder; Bruno R da Costa; Sebastian Ewen; Sean S Scholz; William Wijns; Thomas F Lüscher; Patrick W Serruys; Elazer R Edelman; Davide Capodanno; Michael Böhm; Peter Jüni; Felix Mahfoud
Journal:  Eur Heart J       Date:  2020-07-14       Impact factor: 35.855

Review 5.  Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.

Authors:  Felix Mahfoud; Roland E Schmieder; Michel Azizi; Atul Pathak; Horst Sievert; Costas Tsioufis; Thomas Zeller; Stefan Bertog; Peter J Blankestijn; Michael Böhm; Michel Burnier; Gilles Chatellier; Isabelle Durand Zaleski; Sebastian Ewen; Guido Grassi; Michael Joner; Sverre E Kjeldsen; Melvin D Lobo; Chaim Lotan; Thomas Felix Lüscher; Gianfranco Parati; Patrick Rossignol; Luis Ruilope; Faisal Sharif; Evert van Leeuwen; Massimo Volpe; Stephan Windecker; Adam Witkowski; William Wijns
Journal:  Eur Heart J       Date:  2017-11-21       Impact factor: 29.983

6.  Contrast Induced Acute Kidney Injury and its Impact on Mid-Term Kidney Function, Cardiovascular Events and Mortality.

Authors:  Werner Ribitsch; Joerg H Horina; Franz Quehenberger; Alexander R Rosenkranz; Gernot Schilcher
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

7.  Clinical benefits and safety of renal denervation in severe arterial hypertension: A long-term follow-up study.

Authors:  Tino Naduvathumuriyil; Ulrike Held; Klaus Steigmiller; Andrea Denegri; Silviya Cantatore; Slayman Obeid; Andreas J Flammer; Frank Ruschitzka; Thomas F Lüscher; Isabella Sudano
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-03       Impact factor: 3.738

8.  Prognostic Value of Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements in Adults With Congenital Heart Disease.

Authors:  Vivan J M Baggen; Sara J Baart; Annemien E van den Bosch; Jannet A Eindhoven; Maarten Witsenburg; Judith A A E Cuypers; Jolien W Roos-Hesselink; Eric Boersma
Journal:  J Am Heart Assoc       Date:  2018-03-26       Impact factor: 5.501

9.  Effects of bifocals on visual acuity in children with Down syndrome: a randomized controlled trial.

Authors:  Christine de Weger; Nienke Boonstra; Jeroen Goossens
Journal:  Acta Ophthalmol       Date:  2018-10-27       Impact factor: 3.761

10.  Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies.

Authors:  Felix Mahfoud; Michel Azizi; Sebastian Ewen; Atul Pathak; Christian Ukena; Peter J Blankestijn; Michael Böhm; Michel Burnier; Gilles Chatellier; Isabelle Durand Zaleski; Guido Grassi; Michael Joner; David E Kandzari; Ajay Kirtane; Sverre E Kjeldsen; Melvin D Lobo; Thomas F Lüscher; John William McEvoy; Gianfranco Parati; Patrick Rossignol; Luis Ruilope; Markus P Schlaich; Atif Shahzad; Faisal Sharif; Andrew S P Sharp; Horst Sievert; Massimo Volpe; Michael A Weber; Roland E Schmieder; Costas Tsioufis; William Wijns
Journal:  Eur Heart J       Date:  2020-04-21       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.